Teladoc Health (NYSE:TDOC) Issues FY 2026 Earnings Guidance

Teladoc Health (NYSE:TDOC) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of -0.950–0.750 for the period, compared to the consensus estimate of -0.810. The company issued revenue guidance of $2.4 billion, compared to the consensus revenue estimate of $2.4 billion. Teladoc Health also updated its Q4 2026 guidance to -0.230–0.030 EPS.

Teladoc Health Trading Down 1.9%

Shares of TDOC traded down $0.17 during midday trading on Friday, reaching $8.56. The stock had a trading volume of 3,151,683 shares, compared to its average volume of 5,087,175. Teladoc Health has a one year low of $4.40 and a one year high of $9.89. The firm has a market cap of $1.56 billion, a PE ratio of -9.96 and a beta of 2.14. The firm has a 50 day simple moving average of $6.19 and a 200-day simple moving average of $6.47.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings data on Wednesday, October 28th. The health services provider reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07. The firm had revenue of $605.10 million during the quarter, compared to the consensus estimate of $588.14 million. Teladoc Health had a negative net margin of 6.27% and a negative return on equity of 11.52%. The business’s revenue for the quarter was down 3.4% compared to the same quarter last year. During the same period last year, the business posted ($0.28) earnings per share. As a group, research analysts forecast that Teladoc Health will post -0.92 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on TDOC. Citigroup reduced their price target on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating for the company in a report on Monday, August 3rd. Canaccord Genuity Group cut their target price on Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Stifel Nicolaus increased their target price on Teladoc Health from $5.50 to $6.50 and gave the company a “hold” rating in a report on Thursday. Bank of America raised their target price on shares of Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Teladoc Health in a research report on Wednesday, August 19th. Five research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $7.54.

Insider Buying and Selling

In other news, CEO Charles III sold 17,805 shares of the firm’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $6.10, for a total transaction of $108,610.50. Following the transaction, the chief executive officer owned 465,535 shares in the company, valued at approximately $2,839,763.50. This trade represents a 3.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.70% of the stock is owned by company insiders.

Trending Headlines about Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported third-quarter revenue of $605.1 million, down approximately 3% year over year but above Wall Street expectations. Its $0.15 per-share loss was also narrower than the roughly $0.22-$0.23 consensus estimate. Teladoc Health Reports Third Quarter 2026 Results
• Positive Sentiment: Adjusted EBITDA reached approximately $79 million, exceeding guidance, while improving free cash flow supported the view that Teladoc’s earnings quality and financial discipline are strengthening. Teladoc Health Stock Rebounds on Q3 Results
• Positive Sentiment: BetterHelp’s insurance-related revenue reached $32 million, giving investors early evidence that the mental-health business can diversify beyond direct consumer payments. Teladoc also outlined a plan to exit certain insurance arrangements at a run rate of at least $200 million and repurchase convertible notes. Teladoc Targets BetterHelp Insurance Exit Run Rate
• Neutral Sentiment: Teladoc’s full-year 2026 revenue outlook of $2.4 billion is in line with consensus. The company issued an EPS range of a $0.95 loss to a $0.75 loss, broadly surrounding the $0.81 consensus estimate. Teladoc Provides 2026 Guidance
• Negative Sentiment: Fourth-quarter revenue guidance of $569 million to $615 million has a midpoint below the $601.7 million analyst estimate, while the EPS range of a $0.23 loss to a $0.03 loss indicates that near-term profitability remains uncertain. Analysts have generally maintained “hold” ratings, with at least one price target below the recent trading level. Teladoc Stock Rallies After Q3 Beat

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.